ReproCell Stock

ReproCell FCF Growth

The Year-over-Year Free Cash Flow Growth of ReproCell (4978.T) as of Sep 4, 2026 is 56.04 %. In the previous year, Year-over-Year Free Cash Flow Growth was 37.13 % — a change of 50.90% (higher).

FCF Growth

56.04 %

YoY

50.90%

Last updated:

Year-over-Year Free Cash Flow Growth of ReproCell is 2026 56.04 % . Year-over-Year Free Cash Flow Growth of ReproCell was 2025 37.13 % . It decreases by 50.90% higher compared to the previous year.

The ReproCell FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
19.09 JPY
Jan 1, 2019
4.90 JPY
Jan 1, 2020
-25.23 JPY
Jan 1, 2021
12.49 JPY
Jan 1, 2022
59.13 JPY
Jan 1, 2023
-0.44 JPY
Jan 1, 2024
37.13 JPY
Jan 1, 2025
56.04 JPY
The ReproCell FCF Growth history
YEARFCF GrowthYoY
56.04 %+50.90%
37.13 %-8,542.69%
-0.44 %-100.74%
59.13 %+373.32%
12.49 %-149.52%
-25.23 %-614.96%
4.90 %-74.34%
19.09 %-162.35%
-30.62 %-1,434.73%
2.29 %-100.16%
-1,469.63 %—
Access this data via the Eulerpool API
Get Free API Key

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Year-over-Year Free Cash Flow Growth of ReproCell is 56.04 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth ReproCell since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's ReproCell historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Growth — ReproCell

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — ReproCell